MX393242B - Anticuerpos utiles en diagnosis de cancer - Google Patents
Anticuerpos utiles en diagnosis de cancerInfo
- Publication number
- MX393242B MX393242B MX2020002243A MX2020002243A MX393242B MX 393242 B MX393242 B MX 393242B MX 2020002243 A MX2020002243 A MX 2020002243A MX 2020002243 A MX2020002243 A MX 2020002243A MX 393242 B MX393242 B MX 393242B
- Authority
- MX
- Mexico
- Prior art keywords
- cancer diagnosis
- antibodies useful
- cldn6
- useful
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/91—Cell lines ; Processes using cell lines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2017/072386 WO2019048040A1 (en) | 2017-09-06 | 2017-09-06 | ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER |
| PCT/EP2018/073883 WO2019048489A1 (en) | 2017-09-06 | 2018-09-05 | ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2020002243A MX2020002243A (es) | 2020-07-20 |
| MX393242B true MX393242B (es) | 2025-03-24 |
Family
ID=59858709
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002243A MX393242B (es) | 2017-09-06 | 2018-09-05 | Anticuerpos utiles en diagnosis de cancer |
| MX2022007706A MX2022007706A (es) | 2017-09-06 | 2020-02-27 | Anticuerpos utiles en diagnosis de cancer. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007706A MX2022007706A (es) | 2017-09-06 | 2020-02-27 | Anticuerpos utiles en diagnosis de cancer. |
Country Status (15)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2404936A1 (en) * | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
| WO2019048040A1 (en) | 2017-09-06 | 2019-03-14 | Ganymed Pharmaceuticals Gmbh | ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER |
| CA3177215C (en) | 2017-09-29 | 2026-06-09 | Daiichi Sankyo Company, Limited | Antibody-pyrrolobenzodiazepine derivative conjugate |
| CN119708241A (zh) | 2019-02-15 | 2025-03-28 | 因特格尔莫来库乐有限公司 | 密封蛋白6抗体及其用途 |
| IL307744A (en) * | 2021-04-22 | 2023-12-01 | Astellas Pharma Inc | Anti-CLDN4/anti-CD137 bispecific antibody |
| JP2025528148A (ja) * | 2022-08-09 | 2025-08-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | クローディン－６抗体及びそのコンジュゲート及び使用 |
| CN120282987A (zh) | 2022-11-30 | 2025-07-08 | 因特格尔莫来库乐有限公司 | 包括双特异性型式的针对紧密连接蛋白6的抗体 |
| KR20260015262A (ko) | 2023-05-25 | 2026-02-02 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 암 치료를 위한 클라우딘-6 접합체의 투여량 |
| TW202542202A (zh) * | 2024-01-04 | 2025-11-01 | 美商翰森生物有限責任公司 | 抗體、抗原結合片段及其醫療用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| KR100944575B1 (ko) | 2002-10-17 | 2010-02-25 | 젠맵 에이/에스 | Ｃｄ20에 대한 인간 모노클로날 항체 |
| AU2004272607B2 (en) * | 2003-09-11 | 2008-11-06 | Cornerstone Therapeutics Inc. | Monoclonal antibodies against HMGB1 |
| US20100129929A1 (en) * | 2006-07-27 | 2010-05-27 | Roberto Polakewicz | Tyrosine Phosphorylation Sites |
| RU2537245C2 (ru) * | 2006-10-12 | 2014-12-27 | Чугаи Сейяку Кабусики Кайся | Диагностика и лечение злокачественной опухоли с использованием антитела против ereg |
| WO2009028663A1 (ja) * | 2007-08-30 | 2009-03-05 | Kyowa Hakko Kirin Co., Ltd. | 抗Claudin-3抗体 |
| AU2009203464A1 (en) * | 2008-01-11 | 2009-07-16 | Forerunner Pharma Research Co., Ltd. | Anti-CLDN6 antibody |
| EP3689911B1 (en) * | 2009-11-11 | 2024-08-21 | Astellas Pharma Inc. | Antibodies specific for claudin 6 (cldn6) |
| EP2322555A1 (en) * | 2009-11-11 | 2011-05-18 | Ganymed Pharmaceuticals AG | Antibodies specific for claudin 6 (CLDN6) |
| EP2404936A1 (en) | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
| EP3026064B1 (en) * | 2011-05-13 | 2018-10-17 | Ganymed Pharmaceuticals GmbH | Antibodies for treatment of cancer expressing claudin 6 |
| WO2015014376A1 (en) * | 2013-07-31 | 2015-02-05 | Biontech Ag | Diagnosis and therapy of cancer involving cancer stem cells |
| GB201607534D0 (en) * | 2016-04-29 | 2016-06-15 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| WO2019048040A1 (en) | 2017-09-06 | 2019-03-14 | Ganymed Pharmaceuticals Gmbh | ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER |
-
2017
- 2017-09-06 WO PCT/EP2017/072386 patent/WO2019048040A1/en not_active Ceased
-
2018
- 2018-09-05 CN CN202210691319.8A patent/CN115433283B/zh active Active
- 2018-09-05 EP EP18765858.8A patent/EP3679069B1/en active Active
- 2018-09-05 CN CN201880058261.5A patent/CN111406070A/zh active Pending
- 2018-09-05 SG SG11202000961SA patent/SG11202000961SA/en unknown
- 2018-09-05 MX MX2020002243A patent/MX393242B/es unknown
- 2018-09-05 BR BR112020003694-3A patent/BR112020003694B1/pt active IP Right Grant
- 2018-09-05 US US16/641,160 patent/US11279757B2/en active Active
- 2018-09-05 CA CA3073157A patent/CA3073157A1/en active Pending
- 2018-09-05 KR KR1020237021589A patent/KR20230107371A/ko active Pending
- 2018-09-05 WO PCT/EP2018/073883 patent/WO2019048489A1/en not_active Ceased
- 2018-09-05 AU AU2018327587A patent/AU2018327587B2/en active Active
- 2018-09-05 JP JP2020513799A patent/JP7277439B2/ja active Active
- 2018-09-05 IL IL293017A patent/IL293017A/en unknown
- 2018-09-05 EP EP24212659.7A patent/EP4512830A3/en active Pending
- 2018-09-05 KR KR1020207005756A patent/KR102550489B1/ko active Active
- 2018-09-05 CN CN202410880523.3A patent/CN118852435A/zh active Pending
- 2018-09-05 ES ES18765858T patent/ES2998108T3/es active Active
- 2018-09-05 PL PL18765858.8T patent/PL3679069T3/pl unknown
-
2020
- 2020-02-05 IL IL272487A patent/IL272487B/en unknown
- 2020-02-10 ZA ZA2020/00851A patent/ZA202000851B/en unknown
- 2020-02-27 MX MX2022007706A patent/MX2022007706A/es unknown
-
2022
- 2022-02-07 US US17/666,122 patent/US11919951B2/en active Active
-
2023
- 2023-05-08 JP JP2023076556A patent/JP7882806B2/ja active Active
- 2023-07-28 AU AU2023208203A patent/AU2023208203A1/en active Pending
-
2024
- 2024-01-26 US US18/423,761 patent/US20240209079A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022007706A (es) | Anticuerpos utiles en diagnosis de cancer. | |
| NZ700823A (en) | Antibodies against claudin 18.2 useful in cancer diagnosis | |
| MX2019001184A (es) | Anticuerpos anti-idiotípicos y métodos relacionados. | |
| MX389021B (es) | Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t. | |
| MY202336A (en) | Agonist antibodies that bind human cd137 and uses thereof | |
| PH12018502225A1 (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
| NZ753515A (en) | Methods for treatment of cancer comprising tigit-binding agents | |
| ZA201708265B (en) | Tigit-binding agents and uses thereof | |
| PH12019501635A1 (en) | Anti-tgf-beta antibodies and their use | |
| MX2016012713A (es) | Inmunoreceptores especificos de claudina-6 y epitopos de celulas t. | |
| SA517381703B1 (ar) | C10orf54 - أجسام مضادة لـ واستخداماتها | |
| PH12017500890A1 (en) | Antibody drug conjugates | |
| TN2016000559A1 (en) | Monoclonal antibodies against her2 epitope and methods of use thereof | |
| HK1249854A1 (zh) | 用於治疗癌症的被遗传修饰的nk-92细胞和单克隆抗体 | |
| EP3705494A3 (en) | Antibodies against frizzled proteins and methods of use thereof | |
| WO2015187018A3 (en) | Means and methods for determining t cell recognition | |
| MX2025009320A (es) | Anticuerpos anti-cd19 novedosos | |
| PH12018502275A1 (en) | Interferon beta antibodies and uses thereof | |
| ZA201800830B (en) | Antibodies and assays for detection of cd37 | |
| EA201992317A1 (ru) | Композиции и способы для диагностики рака легких | |
| EA201992316A1 (ru) | Композиции и способы для диагностики рака предстательной железы | |
| PH12022550035A1 (en) | Antibodies which bind to cancer cells and target radionuclides to said cells | |
| PH12019500434A1 (en) | Anti-gm-csf antibodies and uses thereof | |
| EP3778644A3 (en) | Fgfr-tacc fusion proteins and methods thereof | |
| WO2019126594A3 (en) | Antibodies to centrin-1, methods of making, and uses thereof |